Online inquiry

IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2398MR)

This product GTTS-WQ2398MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&EPCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_000733.4; NM_002354.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 4072
UniProt ID P07766; P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2398MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7725MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ406MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ8568MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ1633MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-910
GTTS-WQ2049MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ6851MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ9228MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ15884MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA XMT-1536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW